Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

Diabetes

Volumn 57, Issue 6, 2008, Pages 1723-1729

  Han, Songping ^a   Hagan, Deborah L ^a   Taylor, Joseph R ^a   Xin, Li ^a   Meng, Wei ^a   Biller, Scott A ^a,b   Wetterau, John R ^a,c   Washburn, William N ^a   Whaley, Jean M ^a,d  

^a BRISTOL MYERS SQUIBB   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c Cerenis Therapeutics   (United States)

^d BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG; 2 (3 (4 ETHOXYBENZYL) 4 CHLOROPHENYL) 6 HYDROXYMETHYLTETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; GLUCOSIDE; SGLT2 PROTEIN, RAT; SLC5A1 PROTEIN, HUMAN; SLC5A1 PROTEIN, RAT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG HALF LIFE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLUCOSURIA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; ZUCKER DIABETIC FATTY RAT; ANIMAL; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOLECULAR CLONING; REFERENCE VALUE; ZUCKER RAT;

ADIPOCYTES; ANIMALS; BLOOD GLUCOSE; CELL LINE; CLONING, MOLECULAR; GLUCOSE; GLUCOSIDES; HUMANS; RATS; RATS, ZUCKER; REFERENCE VALUES; SODIUM-GLUCOSE TRANSPORT PROTEINS; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 48249146624     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1472     Document Type: Article

References (32)

1. Moe OW, Berry CA, Rector FC Jr: Renal transport of glucose, amino acids, sodium, chloride and water. In Brenner and Rector's the Kidney. 5th ed. Brenner BM, Ed. Philadelphia, PA, WB Saunders, 1996, p. 375-415
2. Deetjen P, von Baeyer H, Drexel H: Renal glucose transport. In Seldin and Giebisch's the Kidney. 2nd ed. Seldin DW, Giebisch G, Eds. New York, Raven Press, 1992, p. 2873-2888
3. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA: Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79:1510-1515, 1987
4. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA: Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80:1037-1044, 1987
5. Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L: Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 87:561-570, 1991
6. Dimitrakoudis D, Vranic M, Klip A: Effects of hyperglycemia on glucose transporters of the muscle: use of the renal glucose reabsorption inhibitor phlorizin to control glycemia. J Am Soc Nephrol 3:1078-1091, 1992
7. Shi ZQ, Rastogi KS, Lekas M, Efendic S, Drucker DJ, Vranic M: Glucagon response to hypoglycemia is improved by insulin-independent restoration of normoglycemia in diabetic rats. Endocrinology 137:3193-3199, 1996
8. Marette A, Dimitrakoudis D, Shi Q, Rodgers CD, Klip A, Vranic M: Glucose rapidly decreases plasma membrane GLUT4 content in rat skeletal muscle. Endocrine 10:13-18, 1999
9. Jonas JC, Sharma A, Hasenkamp W, Ilkova H, Patane G, Laybutt R, Bonner-Weir S, Weir GC: Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J Biol Chem 274:14112-14121, 1999
10. Kim JK, Zisman A, Fillmore JJ, Peroni OD, Kotani K, Perret P, Zong H, Dong J, Kahn CR, Kahn BB, Shulman GI: Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J Clin Invest 108:153-160, 2001
11. Hediger MA, Rhoads DB: Molecular physiology of sodium-glucose cotrans-porters. Physiol Rev 74:993-1026, 1994
12. Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, Matsu-moto M, Saito A, Tsujihara K, Anai M, Asano T, Kanai Y, Endou H: T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48:1794-1800, 1999
13. Oku A, Ueta K, Nawano M, Arakawa K, Kano-Ishihara T, Matsumoto M, Saito A, Tsujihara K, Anai M, Asano T: Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol 391:183-192, 2000
14. Nawano M, Oku A, Ueta K, Umebayashi I, Ishirahara T, Arakawa K, Saito A, Anai M, Kikuchi M, Asano T: Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats. Am J Physiol Endocrinol Metab 278:E535-E543, 2000
15. Oku A, Ueta K, Arakawa K, Kano-Ishihara T, Matsumoto M, Adachi T, Yasuda K, Tsuda K, Saito A: Antihyperglycemic effect of T-1095 via inhibition of renal Na+ -glucose cotransporters in streptozotocin-induced diabetic rats. Biol Pharm Bull 23:1434-1437, 2000
16. Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, Matsumoto M, Saito A: Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+ )-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132:578-586, 2001
17. Wright EM, Hirayama BA, Loo DF: Active sugar transport in health and disease. J Intern Med 261:32-43, 2007
18. Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA: Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol 263:F459-F465, 1992
19. You G, Lee WS, Barros EJ, Kanai Y, Huo TL, Khawaja S, Wells RG, Nigam SK, Hediger MA: Molecular characteristics of Na(+ )-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 270:29365-29371, 1995
20. Kanai Y, Lee WS, You G, Brown D, Hediger MA: The human kidney low affinity Na+/glucose cotransporter SGLT2: delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93:397-404, 1994
21. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D: Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14:2873-2882, 2003
22. van den Heuvel LP, Assink K, Willemsen M, Monnens L: Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2): Hum Genet 111:544-547, 2002
23. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN: Discovery of dapagli-flozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51:1145-1149, 2008
24. Ren JM, Marshall BA, Mueckler MM, McCaleb M, Amatruda JM, Shulman GI: Overexpression of GLUT4 protein in muscle increases basal and insulin-stimulated whole body glucose disposal in conscious mice. J Clin Invest 95:429-432, 1995
25. Kraegen EW, James DE, Bennett SP, Chisholm DJ: In vivo insulin sensitivity in the rat determined by euglycemic clamp. Am JPhysiol 245:E1-E7, 1983
26. Malathi P, Crane RK: Phlorizin hydrolase: a beta-glucosidase of hamster intestinal brush border membrane. Biochim Biophys Acta 173:245-256, 1969
27. Crespy V, Aprikian O, Morand C, Besson C, Manach C, Demigné C, Rémésy C: Bioavailability of phloretin and phloridzin in rats. J Nutr 131:3227-3230, 2001
28. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J: Phlorizin: a review. Diabetes Metab Res Rev 21:31-38, 2005
29. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M: Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. Pharmacol Exp Ther 320:323-330, 2007
30. Devenny J, Harvey S, Rooney S, Godonis H, Washburn W, Whaley J, Taylor S, Pelleymounter MA: The effect of dapagliflozin (BMS-512148), a selective SGLT2 inhibitor, on body weight in diet-induced obese rats: presented at the 2007 North American Association for the Study of Obesity Annual Meeting. Obesity 15 (Suppl. 9):A121, 2007
31. Pedersen KB, Zhang P, Doumen C, Charbonnet M, Lu D, Newgard CB, Haycock JW, Lange AJ, Scott DK: The promoter for the gene encoding the catalytic subunit of rat glucose-6-phosphatase contains two distinct glucose-responsive regions. Am Physiol Endocrinol Metab 292:E788-E801, 2007
32. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H: Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569-2576, 1999